ENDOWMENT CASE FUNDING | 3
The need for greater investment in research continues.
As the drugs become more sophisticated, new obstacles will emerge that need to be addressed. As a leader in the melanoma community, the MRF is uniquely positioned to address these challenges and support cutting-edge research for years to come. For a newly diagnosed patient or one facing a metastatic diagnosis, the hope of future research that could lead to a positive outcome changes everything.
16 FDA-APPROVED TREATMENTS 22 CLINICAL TRIALS 6 NEW PATENTED THERAPIES 409 SCIENTIFIC PRESENTATIONS 589 RESEARCH GRANT COLLABORATIONS
TO LEARN MORE, VISIT MELANOMA.ORG/RESEARCH-SCIENCE.
inhibitor for metastatic melanoma. 2014
FDA approves the first PD-1 checkpoint
Made with FlippingBook Ebook Creator